KRAS: A Promising Therapeutic Target for Cancer Treatment-Reference-Cited by-同舟云学术

KRAS: A Promising Therapeutic Target for Cancer Treatment

Published:2019-11-15 Issue:23 Volume:19 Page:2081-2097
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Wu Hai-Zhou¹,Xiao Jia-Qi¹,Xiao Song-Shu²,Cheng Yan¹

Affiliation:

1. Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410008, China

2. Department of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, 410008, China

Abstract

: Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. Scientists have not successfully developed drugs that target KRAS, although efforts have been made last three decades. In this review, we highlight the emerging experimental strategies of impairing KRAS membrane localization and the direct targeting of KRAS. We also conclude the combinatorial therapies and RNA interference technology for the treatment of KRAS mutant cancers. Moreover, the virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference152 articles.

1. Hjortland G.O.; Meza-Zepeda L.A.; Beiske K.; Ree A.H.; Tveito S.; Hoifodt H.; Bohler P.J.; Hole K.H.; Myklebost O.; Fodstad O.; Smeland S.; Hovig E.; Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer 2011,11,455

2. Zhou B.; Der C.J.; Cox A.D.; The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol 2016,58,60-69

3. Pylayeva-Gupta Y.; Grabocka E.; Bar-Sagi D.; RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011,11(11),761-774

4. Kim W.; Lee S.; Kim H.S.; Song M.; Cha Y.H.; Kim Y.H.; Shin J.; Lee E.S.; Joo Y.; Song J.J.; Choi E.J.; Choi J.W.; Lee J.; Kang M.; Yook J.I.; Lee M.G.; Kim Y.S.; Paik S.; Kim H.H.; Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth. Genome Res [Epub ahead of Print2018

5. Boutin A.T.; Liao W.T.; Wang M.; Hwang S.S.; Karpinets T.V.; Cheung H.; Chu G.C.; Jiang S.; Hu J.; Chang K.; Vilar E.; Song X.; Zhang J.; Kopetz S.; Futreal A.; Wang Y.A.; Kwong L.N.; DePinho R.A.; Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 2017,31(4),370-382

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma;Medicine;2023-12-29

2. Revealing KRas4b topology on the membrane surface;Biochemical and Biophysical Research Communications;2023-10

3. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations;Lung Cancer;2023-09

4. Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson–Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis;Molecules;2023-06-28

5. Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G12C : expérience du centre hospitalier régional universitaire de Tours;Revue des Maladies Respiratoires;2023-01